[go: up one dir, main page]

MX2018013191A - Compuestos de pirimidina como inhibidores de la quinasa jak. - Google Patents

Compuestos de pirimidina como inhibidores de la quinasa jak.

Info

Publication number
MX2018013191A
MX2018013191A MX2018013191A MX2018013191A MX2018013191A MX 2018013191 A MX2018013191 A MX 2018013191A MX 2018013191 A MX2018013191 A MX 2018013191A MX 2018013191 A MX2018013191 A MX 2018013191A MX 2018013191 A MX2018013191 A MX 2018013191A
Authority
MX
Mexico
Prior art keywords
compounds
kinase inhibitors
pyrimidine compounds
jak kinase
formula
Prior art date
Application number
MX2018013191A
Other languages
English (en)
Other versions
MX377180B (es
Inventor
Fleury Melissa
Marie BEAUSOLEIL Anne-
Hudson Ryan
Kozak Jennifer
R Fatheree Paul
D Podesto Dante
Huang Xiaojun
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of MX2018013191A publication Critical patent/MX2018013191A/es
Publication of MX377180B publication Critical patent/MX377180B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención provee compuestos de fórmula (I): (ver Fórmula) donde las variables se definen en la memoria descriptiva, o una sal farmacéuticamente aceptable de los mismos, que son inhibidores de las quinasas JAK. La invención también provee composiciones farmacéuticas que comprenden tales compuestos, métodos de uso de tales compuestos para tratar enfermedades gastrointestinales y otras enfermedades inflamatorias, y procesos e intermediarios útiles para preparar tales compuestos.
MX2018013191A 2016-04-28 2017-04-27 Compuestos de pirimidina como inhibidores de la quinasa jak. MX377180B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662328737P 2016-04-28 2016-04-28
PCT/US2017/029796 WO2017189822A1 (en) 2016-04-28 2017-04-27 Pyrimidine compounds as jak kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2018013191A true MX2018013191A (es) 2019-02-13
MX377180B MX377180B (es) 2025-03-07

Family

ID=58672793

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013191A MX377180B (es) 2016-04-28 2017-04-27 Compuestos de pirimidina como inhibidores de la quinasa jak.

Country Status (20)

Country Link
US (3) US10028960B2 (es)
EP (1) EP3433253B1 (es)
JP (1) JP6881879B2 (es)
KR (1) KR102244257B1 (es)
CN (1) CN109071529B (es)
AU (1) AU2017258186B2 (es)
BR (1) BR112018072168A2 (es)
CA (1) CA3020506A1 (es)
CL (1) CL2018003060A1 (es)
CO (1) CO2018011408A2 (es)
DK (1) DK3433253T3 (es)
EA (1) EA035226B1 (es)
ES (1) ES2779880T3 (es)
IL (1) IL262386B (es)
MX (1) MX377180B (es)
PT (1) PT3433253T (es)
SG (1) SG11201809342YA (es)
TW (1) TWI726094B (es)
WO (1) WO2017189822A1 (es)
ZA (1) ZA201807179B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03610B (me) 2015-05-28 2020-07-20 Theravance Biopharma R&D Ip Llc Naftiridinska jedinjenja kao inhibitori jak kinaze
EP3865481A1 (en) 2015-11-03 2021-08-18 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
ES2840650T3 (es) 2015-11-03 2021-07-07 Topivert Pharma Ltd Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina y 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inhibidores de la quinasa janus
CN109071529B (zh) * 2016-04-28 2021-08-06 施万生物制药研发Ip有限责任公司 作为jak激酶抑制剂的嘧啶化合物
RS63608B1 (sr) * 2017-10-27 2022-10-31 Theravance Biopharma R&D Ip Llc Pirimidinsko jedinjenje kao inhibitor jak kinaze
US12171764B2 (en) 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
WO2020108516A1 (zh) * 2018-11-27 2020-06-04 江苏豪森药业集团有限公司 含氮杂芳类衍生物调节剂、其制备方法和应用
CN111511738B (zh) * 2018-11-30 2023-01-20 江苏豪森药业集团有限公司 杂芳类衍生物调节剂、其制备方法和应用
JP7482152B2 (ja) * 2019-04-24 2024-05-13 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー 皮膚疾患の処置のためのピリミジンｊａｋ阻害剤 発明の背景
HUE066802T2 (hu) * 2019-04-24 2024-09-28 Theravance Biopharma R&D Ip Llc JAK kináz inhibitor észter és karbonát pirimidin vegyületek
TW202207918A (zh) * 2020-05-14 2022-03-01 美商施萬生物製藥研發Ｉｐ有限責任公司 腸道選擇性ｊａｋ３抑制劑的投與
WO2022076703A1 (en) * 2020-10-09 2022-04-14 Janssen Biotech, Inc. Processes for preparing a pan-jak inhibitor and related intermediate compounds
CN116390922B (zh) * 2020-10-21 2025-07-18 珠海联邦制药股份有限公司 硒杂环类化合物及其应用
WO2023011359A1 (zh) * 2021-08-05 2023-02-09 南京明德新药研发有限公司 桥环类化合物及其应用
CN113883920B (zh) * 2021-10-25 2024-01-23 安徽华铂再生资源科技有限公司 一种降低空分装置空冷塔出口温度的方法
WO2023202706A1 (zh) * 2022-04-21 2023-10-26 南京明德新药研发有限公司 硒杂环类化合物的盐型和晶型及其应用
WO2025040148A1 (zh) * 2023-08-22 2025-02-27 北京普祺医药科技股份有限公司 一种用于jak抑制剂的外用凝胶及其用途
TW202515852A (zh) * 2023-09-15 2025-04-16 美商莫菲克醫療股份有限公司 抑制人類整合素α４β７

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
MXPA03005609A (es) 2000-12-21 2003-10-06 Vertex Pharma Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
AU2005322855B2 (en) * 2004-12-30 2012-09-20 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
ATE508126T1 (de) 2005-11-16 2011-05-15 Vertex Pharma Als kinaseinhibitoren geeignete aminopyrimidine
JP2009541480A (ja) 2006-06-30 2009-11-26 アストラゼネカ アクチボラグ 癌の治療において有用なピリミジン誘導体
AU2007269540B2 (en) 2006-07-05 2013-06-27 Exelixis, Inc. Methods of using IGF1R and Abl kinase modulators
JP2015504876A (ja) 2011-12-22 2015-02-16 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト セリン／トレオニンキナーゼ阻害剤としての２，４−ジアミン−ピリミジン誘導体
WO2015094803A1 (en) * 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
NO2721710T3 (es) * 2014-08-21 2018-03-31
ME03610B (me) 2015-05-28 2020-07-20 Theravance Biopharma R&D Ip Llc Naftiridinska jedinjenja kao inhibitori jak kinaze
CN109071529B (zh) * 2016-04-28 2021-08-06 施万生物制药研发Ip有限责任公司 作为jak激酶抑制剂的嘧啶化合物

Also Published As

Publication number Publication date
CL2018003060A1 (es) 2018-12-14
EP3433253B1 (en) 2020-02-12
BR112018072168A2 (pt) 2019-02-12
US20170312280A1 (en) 2017-11-02
IL262386B (en) 2021-08-31
SG11201809342YA (en) 2018-11-29
CA3020506A1 (en) 2017-11-02
TW201739747A (zh) 2017-11-16
EA035226B1 (ru) 2020-05-19
US20200046709A1 (en) 2020-02-13
JP2019514903A (ja) 2019-06-06
JP6881879B2 (ja) 2021-06-02
US20180303836A1 (en) 2018-10-25
EP3433253A1 (en) 2019-01-30
ZA201807179B (en) 2019-08-28
KR102244257B1 (ko) 2021-04-26
AU2017258186A1 (en) 2018-11-15
CO2018011408A2 (es) 2018-11-13
AU2017258186B2 (en) 2020-09-17
ES2779880T3 (es) 2020-08-20
US11110095B2 (en) 2021-09-07
CN109071529A (zh) 2018-12-21
CN109071529B (zh) 2021-08-06
KR20190002591A (ko) 2019-01-08
MX377180B (es) 2025-03-07
US10028960B2 (en) 2018-07-24
US10485803B2 (en) 2019-11-26
PT3433253T (pt) 2020-04-30
DK3433253T3 (da) 2020-04-06
EA201892436A1 (ru) 2019-04-30
WO2017189822A1 (en) 2017-11-02
TWI726094B (zh) 2021-05-01
IL262386A (en) 2018-11-29

Similar Documents

Publication Publication Date Title
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
CO2017012267A2 (es) Compuestos de naftiridina como inhibidores de la quinasa jak
CO2020001469A2 (es) Compuestos bicíclicos de pirazol y triazolo como inhibidores de las cinasas jak
MX375323B (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos.
CL2018001145A1 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
MX389349B (es) Derivados de ácido borónico y usos terapéuticos de los mismos.
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
MX2019010541A (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak.
EA201691302A1 (ru) Новые гетероциклические соединения
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
CU20160167A7 (es) Compuestos de pirazolopiridinas y pirazolopirimidinas útiles en el tratamiento de condiciones alérgicas y respiratorias
MX385082B (es) Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos.
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201592199A1 (ru) Производные бипиразола в качестве ингибиторов jak
EA201792689A1 (ru) Производные 2-(пиразолопиридин-3-ил)пиримидина в качестве ингибиторов jak
EA202091016A1 (ru) Пиримидиновое соединение в качестве ингибитора jak киназы
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2
EA201691670A1 (ru) Тетразолонзамещенные дигидропиридиноновые ингибиторы mgat2
CO2019008110A2 (es) Activador de nrf2
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
EA201600002A1 (ru) Производные пролекарства замещенных триазолопиридинов
EA202192822A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы
EA201892188A1 (ru) Соединения пирролотриазина в качестве ингибиторов tam

Legal Events

Date Code Title Description
FG Grant or registration